Furthermore, in patients with oligo-residual disease—where individuals with EGFR-mutated NSCLC transition to an oligometastatic state following a period of EGFR-TKI therapy—there is emerging evidence suggesting that the addition of local ablative therapy (LAT) to target residual lesions may confer further clinical benefit [15]. Here, EGFR is linked to non-small cell lung carcinoma.